Related Experiment Videos
Reduced bone density at completion of chemotherapy for a malignancy
P Arikoski1, J Komulainen, P Riikonen
1Department of Pediatrics, Kuopio University Hospital, Finland. Arikoski@messi.uku.fi
Archives of Disease in Childhood
|May 18, 1999
Summary
Children with cancer face a risk of osteopenia, a condition of reduced bone density. Bone mineral density (BMD) monitoring after chemotherapy is crucial for early intervention to prevent further bone loss.
Area of Science:
- Pediatric Oncology
- Pediatric Endocrinology
- Bone Metabolism
Background:
- Osteoporosis and pathological fractures are known complications in children with malignancies.
- Assessing bone health in pediatric cancer patients is critical during and after treatment.
Purpose of the Study:
- To determine the degree of osteopenia in children with malignancies upon completion of chemotherapy.
- To evaluate bone mineral density (BMD) in pediatric cancer survivors.
Main Methods:
- Dual-energy X-ray absorptiometry (DXA) was used to measure lumbar spine and femoral neck BMD in children with acute lymphoblastic leukemia (ALL) and other malignancies.
- Apparent volumetric density was calculated to adjust for bone size.
- Results were compared to 113 healthy controls and expressed as standardized Z-scores.
Main Results:
- Patients with ALL showed significantly reduced lumbar volumetric BMD and femoral areal and volumetric BMD.
- Patients with other malignancies exhibited significantly decreased femoral areal and volumetric BMD.
- Both groups demonstrated significant osteopenia compared to healthy controls.
Conclusions:
- Children with malignancies are at risk for developing osteopenia.
- Follow-up BMD assessments post-chemotherapy are essential for identifying patients with impaired peak bone mass development.
- Interventions may be necessary to prevent further skeletal mass decrease and preserve BMD in pediatric cancer survivors.